

Title (en)

TREATMENT OF REWARD DEFICIENCY SYNDROME

Title (de)

BEHANDLUNG VON RDS (BELOHNUNG-MANGEL SYNDROM)

Title (fr)

TRAITEMENT DU SYNDROME D'INSATISFACTION

Publication

**EP 0979092 A2 20000216 (EN)**

Application

**EP 98920019 A 19980429**

Priority

- US 9808684 W 19980429
- US 4439497 P 19970429

Abstract (en)

[origin: WO9848785A2] Enhancement of attentional processing is attained by administration of an endorphinase inhibitor or enkephalinase inhibitor and optionally, a dopamine precursor, or a serotonin precursor, a GABA precursor, or an endorphin or enkephalinase releaser, or certain herbal compounds including Rhodiola rosea extract (Pharmaline) and/or Huperzine. These components promote restoration of normal neurotransmitter function and the components combined enhance the release of dopamine at the nucleus accumbens and are non-addictive. Use of the dopamine precursors L-phenylalanine, or L-Tyrosine, the enkephalinase inhibitor D-phenylalanine, and/or the serotonin precursor -hydroxytryptophan and a natural acetylcholinesterase inhibitor and chromium salts (i.e. picolinate, nicotinate, etc.) is especially preferred, but not limited to assist in relieving symptoms associated with brain phenylalanine deficiency.

IPC 1-7

**A61K 33/24; A61K 38/00; A61K 35/78**

IPC 8 full level

**A61K 33/24** (2019.01); **A61K 45/00** (2006.01); **A61K 31/198** (2006.01); **A61K 31/28** (2006.01); **A61K 31/465** (2006.01); **A61K 31/555** (2006.01); **A61K 36/41** (2006.01); **A61K 38/00** (2006.01); **A61K 45/06** (2006.01); **A61K 48/00** (2006.01); **A61P 3/04** (2006.01); **A61P 25/00** (2006.01); **A61P 25/18** (2006.01); **A61P 25/20** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 25/30** (2006.01); **A61P 43/00** (2006.01)

CPC (source: EP KR US)

**A61K 31/195** (2013.01 - KR); **A61K 31/465** (2013.01 - EP); **A61K 31/555** (2013.01 - EP); **A61K 33/24** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP); **A61P 3/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/20** (2017.12 - EP); **A61P 25/24** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **A61P 25/30** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C12Q 1/6883** (2013.01 - EP); **C12Q 2600/156** (2013.01 - EP)

Citation (search report)

See references of WO 9848785A2

Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)

**WO 9848785 A2 19981105; WO 9848785 A3 19990401; WO 9848785 A9 19990520**; AU 7267798 A 19981124; CA 2288990 A1 19981105; CN 1261801 A 20000802; EP 0979092 A2 20000216; IL 132634 A0 20010319; IS 5233 A 19991028; JP 2002511850 A 20020416; KR 20010020422 A 20010315; NO 995257 D0 19991028; NO 995257 L 19991227

DOCDB simple family (application)

**US 9808684 W 19980429**; AU 7267798 A 19980429; CA 2288990 A 19980429; CN 98806484 A 19980429; EP 98920019 A 19980429; IL 13263498 A 19980429; IS 5233 A 19991028; JP 54736498 A 19980429; KR 19997010047 A 19991029; NO 995257 A 19991028